thalidomide has been researched along with AIDS Wasting Syndrome in 25 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is being investigated for its potential use in treating HIV wasting syndrome and other HIV-related conditions." | 3.70 | Clinical pharmacology of thalidomide. ( Trapnell, CB, 1998) |
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| "Thalidomide therapy was associated with mild to moderate rashes and fevers, but not peripheral neuropathy." | 2.69 | Thalidomide for the treatment of AIDS-associated wasting. ( Fessel, WJ; Fierer, DS; Haslett, PA; Kaplan, G; Kook, KA; Mulligan, K; Schambelan, M; Smith, LG; Stirling, D; Thomas, S, 2000) |
| "Although the HIV wasting syndrome has become a far less common manifestation of advanced disease since the introduction of highly active therapies, much has been learned about a number of potential therapeutic interventions." | 2.41 | Potential interventions for HIV/AIDS wasting: an overview. ( Abrams, DI, 2000) |
| "Thalidomide is a drug associated with devastating side effects." | 1.30 | Thalidomide's long and winding road. ( Hanna, L, 1998) |
| "Thalidomide has shown promise in treating wasting and contact information is provided for a compassionate use program." | 1.30 | Approaches to the AIDS Wasting Syndrome. ( Corcoran, C, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (80.00) | 18.2507 |
| 2000's | 5 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Woolard, S | 1 |
| Anand, G | 1 |
| Sharp, M | 1 |
| Getty, J | 1 |
| Klausner, JD | 1 |
| Brower, V | 1 |
| Wanke, C | 1 |
| Bronner, GM | 1 |
| Koks, CH | 1 |
| Beijnen, JH | 1 |
| Corcoran, C | 2 |
| Grinspoon, S | 1 |
| Kaplan, G | 1 |
| Thomas, S | 1 |
| Fierer, DS | 1 |
| Mulligan, K | 1 |
| Haslett, PA | 1 |
| Fessel, WJ | 1 |
| Smith, LG | 1 |
| Kook, KA | 1 |
| Stirling, D | 1 |
| Schambelan, M | 1 |
| Abrams, DI | 1 |
| MacDougall, DS | 3 |
| Trapnell, CB | 1 |
| Hanna, L | 1 |
| Highleyman, L | 1 |
| Osoegawa, M | 1 |
| Kira, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00006158] | Phase 2 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for thalidomide and AIDS Wasting Syndrome
| Article | Year |
|---|---|
Wasting syndrome in HIV/AIDS patients. A guide to prevention and management.
Topics: Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; HIV Wasting Syndrome; Human Growth Hormo | 2001 |
Single-agent/combination therapy of human immunodeficiency virus-related wasting.
Topics: Anabolic Agents; Androgens; Appetite Stimulants; Drug Therapy, Combination; Growth Hormone; HIV Wast | 1998 |
Treatments for wasting in patients with the acquired immunodeficiency syndrome.
Topics: Appetite Stimulants; Dietary Supplements; Exercise; Female; HIV Wasting Syndrome; Human Growth Hormo | 1999 |
Potential interventions for HIV/AIDS wasting: an overview.
Topics: Anabolic Agents; Anti-HIV Agents; Appetite Stimulants; Clinical Trials as Topic; Female; HIV Wasting | 2000 |
[HIV wasting syndrome].
Topics: Antiretroviral Therapy, Highly Active; Diagnosis, Differential; Growth Hormone; HIV Wasting Syndrome | 2001 |
2 trials available for thalidomide and AIDS Wasting Syndrome
| Article | Year |
|---|---|
Thalidomide for the treatment of AIDS-associated wasting.
Topics: Adult; Anti-HIV Agents; Body Composition; Body Weight; CD4 Lymphocyte Count; Double-Blind Method; En | 2000 |
Thalidomide trial for diarrhea.
Topics: Drug Monitoring; HIV Wasting Syndrome; Humans; Immunosuppressive Agents; Randomized Controlled Trial | 1996 |
18 other studies available for thalidomide and AIDS Wasting Syndrome
| Article | Year |
|---|---|
How drug's rebirth as treatment for cancer fueled price rises.
Topics: Drug Industry; HIV Wasting Syndrome; Humans; Multiple Myeloma; Neoplasms; Thalidomide | 2004 |
Thalidomide use is associated with weight gain in HIV-1-positive clients.
Topics: Adult; Female; HIV Infections; HIV Wasting Syndrome; HIV-1; Humans; Immunosuppressive Agents; Male; | 1997 |
Thalidomide checks might have saved Redux.
Topics: Appetite Depressants; Drug Approval; Fenfluramine; Heart Valve Diseases; HIV Wasting Syndrome; Patie | 1997 |
A cautious comeback for thalidomide.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Graft vs Host Disease; HIV Wasting Syndrome; Hum | 1998 |
Thalidomide pros and cons.
Topics: Double-Blind Method; Female; HIV Infections; HIV Wasting Syndrome; Humans; Immunosuppressive Agents; | 1998 |
[Thalidomide once more in the spotlight].
Topics: Adult; Dermatologic Agents; Drug Approval; Female; HIV Wasting Syndrome; Humans; Immunosuppressive A | 1999 |
Positive results reported for thalidomide in AIDS wasting.
Topics: Body Weight; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; HIV Wasting Sy | 1997 |
Measurement of body composition: the search for a standard.
Topics: Adult; Biomarkers; Body Water; Extracellular Space; Female; HIV Infections; HIV Wasting Syndrome; Hu | 1997 |
Weight loss update.
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Female; Growth Hormone; HIV Infections; | 1996 |
Thalidomide study.
Topics: Clinical Trials as Topic; Drug Approval; HIV Wasting Syndrome; Humans; Oral Ulcer; Placebos; Pregnan | 1997 |
NIH conference on AIDS wasting syndrome. National Institutes of Health.
Topics: Appetite; Body Composition; Child; Energy Metabolism; Exercise; HIV Infections; HIV Wasting Syndrome | 1997 |
The rehabilitation of thalidomide.
Topics: Abnormalities, Drug-Induced; CD4 Lymphocyte Count; Conflict of Interest; Contraception; Drug Approva | 1998 |
Clinical pharmacology of thalidomide.
Topics: Half-Life; HIV Wasting Syndrome; Humans; Hydrolysis; Stereoisomerism; Teratogens; Thalidomide | 1998 |
Thalidomide's long and winding road.
Topics: Abnormalities, Drug-Induced; Clinical Trials as Topic; Drug Approval; Female; Health Services Access | 1998 |
The thalidomide comeback.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infection | 1998 |
Approaches to the AIDS Wasting Syndrome.
Topics: AIDS-Related Opportunistic Infections; Anabolic Agents; Appetite Stimulants; Dronabinol; Exercise; F | 1998 |
Simply stated...are people still wasting?
Topics: AIDS-Related Opportunistic Infections; Appetite Stimulants; Energy Intake; Growth Hormone; HIV Infec | 1998 |
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |